HealthDaily digest, October 23, 2026
AI Drug Discovery Attracts Major Investment
Pathos AI, an oncology-focused drug discovery company powered by artificial intelligence, has secured substantial new funding that nearly doubles its valuation. The investment signals strong market confidence in AI-driven approaches to developing cancer treatments.
Pathos AI Raises $237 Million for AI-Powered Cancer Drug Discovery
Pathos AI closed a Series E funding round of $237 million, bringing the company's valuation to $3 billion—nearly double its May 2025 valuation. The round involves partnerships with Tempus data and Bristol Myers Squibb, combining data analysis with drug development capabilities.
Why it matters: This demonstrates growing investor confidence in AI-driven drug discovery and shows how AI tools are accelerating the path from research to clinical development for cancer treatments.
Sources: via Techmeme · STAT News